Hansen, A.H.; Andersen, K.I.H.; Xin, L.; Krigslund, O.; Behrendt, N.; Engelholm, L.H.; Bang-Bertelsen, C.H.; Schoffelen, S.; Qvortrup, K.
A HER2 Specific Nanobody–Drug Conjugate: Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models. Molecules 2025, 30, 391.
https://doi.org/10.3390/molecules30020391
AMA Style
Hansen AH, Andersen KIH, Xin L, Krigslund O, Behrendt N, Engelholm LH, Bang-Bertelsen CH, Schoffelen S, Qvortrup K.
A HER2 Specific Nanobody–Drug Conjugate: Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models. Molecules. 2025; 30(2):391.
https://doi.org/10.3390/molecules30020391
Chicago/Turabian Style
Hansen, Anders H., Kasper I. H. Andersen, Li Xin, Oliver Krigslund, Niels Behrendt, Lars H. Engelholm, Claus H. Bang-Bertelsen, Sanne Schoffelen, and Katrine Qvortrup.
2025. "A HER2 Specific Nanobody–Drug Conjugate: Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models" Molecules 30, no. 2: 391.
https://doi.org/10.3390/molecules30020391
APA Style
Hansen, A. H., Andersen, K. I. H., Xin, L., Krigslund, O., Behrendt, N., Engelholm, L. H., Bang-Bertelsen, C. H., Schoffelen, S., & Qvortrup, K.
(2025). A HER2 Specific Nanobody–Drug Conjugate: Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models. Molecules, 30(2), 391.
https://doi.org/10.3390/molecules30020391
